StemCell Therapy

Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States

WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting. All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGenes advanced precision medicine capabilities and our commitment to transform the lives of cancer patients, said Andrew Feinberg, President & CEO at BostonGene.

Details of abstract presentations are as follows:

Abstract Number: 8055*

Title: Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance

Session: Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia

Presenter: Krystle Nomie, PhD, BostonGene

Poster: 388

Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: 6561*

Title: Immune functional portraits of head and neck cancer using next generation sequencing

Session: Head and Neck Cancer

Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Poster: 222

BostonGenes comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.

Research conducted with Massachusetts General Hospital

Abstract Number: 8054*

Title: Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients

Session Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia

Presenter: Cody Ramirez at Washington University in St Louis

Poster: 387

Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.

Research conducted with Washington University in St Louis

Abstract Number: e20065

Title: Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma

First Author: Krystle Nomie, PhD, BostonGene

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: e21026

Title: Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies

First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Research conducted with Massachusetts General Hospital

Abstract Number: e17106

Title: Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma

First Author: James Hsieh, MD, PhD at Washington University in St. Louis

Research conducted with Washington University in St Louis

Abstract Number: e17506

Title: Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome

First Author: Eric H. Kim, MD at Washington University in St. Louis

Research conducted with Washington University in St Louis

*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGenes unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGenes mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005217/en/

Link:
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020 - BioSpace

This entry was posted on May 19, 2020 at 5:47 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |